2000
Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone
McDougle C, Scahill L, McCracken J, Aman M, Tierney E, Arnold L, Freeman B, Martin A, McGough J, Cronin P, Posey D, Riddle M, Ritz L, Swiezy N, Vitiello B, Volkmar F, Votolato N, Walson P. Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone. Child And Adolescent Psychiatric Clinics Of North America 2000, 9: 201-224. PMID: 10674197, DOI: 10.1016/s1056-4993(18)30142-1.Peer-Reviewed Original ResearchConceptsOpen-label trialDA neuronal systemsSafety of risperidoneStudy of RisperidonePlacebo-controlled studyUse of risperidoneExtrapyramidal side effectsTarget of pharmacotherapyTreatment of childrenImpaired social behaviorLong-term effectivenessPreclinical evidenceReceptor blockadeTypical antipsychoticsControlled StudyFirst drugPathophysiology of autismLower riskShort-term benefitsSide effectsRisperidonePotent effectsSymptoms of autismNeuronal systemsEnhanced efficacy
1996
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L. A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder. JAMA Psychiatry 1996, 53: 1001-1008. PMID: 8911223, DOI: 10.1001/archpsyc.1996.01830110037005.Peer-Reviewed Original ResearchConceptsStudy of FluvoxamineAutistic disorderSelective serotonin uptake inhibitorAdverse cardiovascular eventsPlacebo-controlled trialWeeks of treatmentSerotonin uptake inhibitorSerotonin neurotransmitter systemShort-term treatmentCardiovascular eventsPlacebo groupMild sedationNeurotransmitter systemsTreatment responseSafe drugUptake inhibitorFluvoxamineSymptoms of autismFluvoxamine maleateDisordersPlaceboAutistic behaviorPatientsAdultsSymptoms